Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A cancer drug which has potential to stop rare tumours returning has been refused for use on the NHS owing to a lack of evidence, the health watchdog said today.
Glivec (imatinib) is already recommended as a treatment for patients with gastrointestinal stromal tumours (Gist) that cannot be removed by surgery.
In its latest appraisal, the National Institute for Health and Clinical Excellence (Nice) examined whether Glivec should also be given to patients whose tumour has been removed and who are at risk of the cancer recurring.
It concluded there was a lack of evidence to show whether Glivec in this setting extended life expectancy and it was unclear how long treatment should be continued for.
Nice also expressed concerns about resistance to the drug developing, saying this could render the drug ineffective if a patient needs it when their cancer has come back.
The watchdog said it would review the situation in 2011 after more evidence is published.
About 900 people in the UK develop a Gist each year, mostly between the ages of 50 and 60.
Andrew Dillon, chief executive of Nice, said: "At around £19,500 per patient per year, this is an expensive drug, and we need to be more confident about how well it works and what its side-effects are before we consider recommending it for use in the NHS.
"The Appraisal Committee did, however, recommend that an early review date should be set for this appraisal so that evidence on the impact of adjuvant imatinib treatment on overall survival can be considered as soon as results from ongoing trials become available.
"Nice already recommends imatinib for patients with chronic myeloid leukaemia and for those with gastrointestinal stromal tumours that cannot be removed by surgery."
The announcement comes after Nice rejected the drug Avastin for people with advanced bowel cancer.
Clinical data submitted by Roche to Nice showed Avastin can typically offer patients an extra six weeks of life when added to chemotherapy.
Patients typically lived 21.3 months compared with 19.9 months with chemotherapy alone.
Avastin costs almost £21,000 per patient and an estimated 6,500 people per year could be eligible for the dru
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments